A5029611137- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Cancer therapeutics and mechanisms
- Gallbladder and Bile Duct Disorders
- Chemotherapy-related skin toxicity
- Clinical Nutrition and Gastroenterology
- Lung Cancer Treatments and Mutations
- Stoma care and complications
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Clostridium difficile and Clostridium perfringens research
- Neuroendocrine Tumor Research Advances
- Pediatric Hepatobiliary Diseases and Treatments
Saiseikai Kumamoto Hospital
2022-2025
762 Background: Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF) is a standard regimen after gemcitabine-based chemotherapy (CTx) for unresectable or recurrent pancreatic cancer (urPC) patients. Neutropenia caused by systemic CTx has been reported to be prognostic marker in several cancers, however, the relationship between neutropenia efficacy of NFF urPC patients unknown. Therefore, we initiated prospective observational study investigate whether can real-world (NN-2401),...
Abstract The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from who were treated NFF to investigate this relationship. Neutropenia was assessed according the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1–4), B (grades 0–1 2–4), C 0–2 3–4). primary endpoint...
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (NFF) (n = 102), S-1 57), or FOLFIRINOX 14) as treatment. Median overall survival (OS) in the NFF group was 9.08 months, significantly better than (4.90 P 0.002). had a...
706 Background: Nanoliposomal irinotecan (NAL-IRI) and fluorouracil with folinic acid (NFF) is the standard regimen after gemcitabine-based therapy for unresectable or recurrent pancreatic cancer (urPC). We conducted this NAPOLEON-2 study to investigate efficacy safety of NFF explore predictive prognostic factors, retrospectively prospectively, in real world. previously reported interim analysis retrospective data 6 months end collection ( Ann Oncol. 2022;33(suppl 4): S289-S290). Here, we...
Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) progression-free (PFS) in patients with pancreatic cancer, compared gemcitabine (GEM). However, whether PFS is a surrogate marker of OS cancer chemotherapy focusing on FOLFIRINOX or GEM plus nab-paclitaxel remains unknown. We aimed to verify can be prognosis prediction. Methods: This was an integrated analysis the NAPOLEON study retrospective cohort NAPOLEON-2 study—a multicenter...
705 Background: Nanoliposomal irinotecan plus fluorouracil and folinic acid (nal-IRI/FU/LV; NFF) is the standard regimen after gemcitabine-based therapy for unresectable or recurrent pancreatic cancer (urPC). However, efficacy safety of NFF in patients who previously received irinotecan-based chemotherapy remain unclear. Methods: This retrospective study collected data from with urPC at least one previous before receiving 21 hospitals Japan between June 2020 May 2021 (NAPOLEON-2 study). We...
Abstract Background: Few standard second-line treatment options have been established yet for the of patients with unresectable pancreatic cancer refractory to first-line gemcitabine plus nab–paclitaxel (GnP) therapy. The aim this study was compare outcomes nanoliposomal irinotecan + 5-fluorouracil/folinic acid (Nal-IRI 5-FU/LV), S-1, and FOLFIRINOX as regimens in previously treated GnP Methods: This a pooled analysis two multicenter retrospective studies; NAPOLEON-1 study, which who had...
<title>Abstract</title> This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (Nal-IRI 5-FU/LV) (n = 102), S-1 57), or FOLFIRINOX 14) as treatment. Median overall survival (OS) in the Nal-IRI 5-FU/LV group was 9.08 months,...